华安国证生物医药ETF发起式联接A(012598)利润分配表
|
2024-06-30 |
2023-12-31 |
2023-06-30 |
2022-12-31 |
收入 |
-40,703,722.82 |
-13,244,471.23 |
-16,847,859.38 |
-9,791,396.60 |
利息合计 |
17,640.35 |
14,854.47 |
11,060.57 |
11,375.65 |
其中:存款利息收入 |
17,640.35 |
14,854.47 |
11,060.57 |
11,375.65 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益合计 |
-11,918,528.53 |
-2,034,595.96 |
-2,194,459.84 |
-4,315,756.40 |
其中:股票投资收益 |
- |
-2,747,094.75 |
-2,725,096.63 |
-4,560,432.60 |
基金投资收益 |
-11,918,528.53 |
- |
- |
- |
债券投资收益 |
- |
- |
- |
- |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
- |
712,498.79 |
530,636.79 |
244,676.20 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
-28,849,305.07 |
-11,291,692.78 |
-14,709,425.73 |
-5,522,409.58 |
其他收入 |
46,470.43 |
66,963.04 |
44,965.62 |
35,393.73 |
费用 |
205,818.82 |
422,189.43 |
311,328.19 |
317,743.01 |
管理人报酬 |
17,479.39 |
224,036.63 |
162,331.46 |
183,543.86 |
基金托管费 |
3,495.86 |
44,807.35 |
32,466.34 |
36,708.79 |
销售服务费 |
95,299.82 |
82,333.89 |
59,459.42 |
54,251.55 |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
89,543.75 |
71,011.56 |
57,070.97 |
43,238.81 |
利润总额 |
-40,909,541.64 |
-13,666,660.66 |
-17,159,187.57 |
-10,109,139.61 |